KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Other Gross PP&E Adjustments (2016 - 2026)

Pacific Biosciences Of California has reported Other Gross PP&E Adjustments over the past 15 years, most recently at $60.1 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 23.06% year-over-year to $60.1 million; the TTM value through Dec 2025 reached $60.1 million, down 23.06%, while the annual FY2025 figure was $60.1 million, 23.06% down from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $60.1 million at Pacific Biosciences Of California, up from -$43.6 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $78.2 million in Q4 2024 and troughed at -$51.2 million in Q1 2024.
  • A 5-year average of -$14.7 million and a median of -$36.5 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • On a YoY basis, Other Gross PP&E Adjustments climbed as much as 69.38% in 2022 and fell as far as 130.72% in 2022.
  • Year by year, Other Gross PP&E Adjustments stood at $29.3 million in 2021, then skyrocketed by 69.38% to $49.7 million in 2022, then rose by 20.85% to $60.0 million in 2023, then soared by 30.17% to $78.2 million in 2024, then fell by 23.06% to $60.1 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for PACB at $60.1 million in Q4 2025, -$43.6 million in Q3 2025, and -$45.5 million in Q2 2025.